Galapagos NV (GLPG) Getting Somewhat Favorable Press Coverage, Study Finds
Press coverage about Galapagos NV (NASDAQ:GLPG) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galapagos NV earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6932643729476 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern’s analysis:
- Galapagos NV (GLPG) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron (finance.yahoo.com)
- Galapagos NV (GLPG) Sees Large Decline in Short Interest (americanbankingnews.com)
- Form 6-K GALAPAGOS NV For: Sep 27 (streetinsider.com)
- GALAPAGOS : and MorphoSys report first promising signs of clinical activity in a.. (4-traders.com)
Shares of Galapagos NV (NASDAQ GLPG) opened at 102.75 on Tuesday. Galapagos NV has a 52 week low of $57.16 and a 52 week high of $103.54. The stock has a 50 day moving average price of $100.87 and a 200-day moving average price of $100.87.
A number of analysts have commented on GLPG shares. Stifel Nicolaus raised Galapagos NV from a “hold” rating to a “buy” rating and lifted their price target for the stock from $83.00 to $101.00 in a research report on Friday, August 11th. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Friday, July 14th. BTIG Research restated a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research note on Tuesday, June 20th. BidaskClub raised Galapagos NV from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Finally, Nomura lifted their target price on Galapagos NV from $108.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. Galapagos NV currently has an average rating of “Buy” and an average target price of $103.71.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/galapagos-nv-glpg-getting-somewhat-favorable-press-coverage-study-finds/1604313.html.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.